Advisory Research’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Advisory Research’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,829	Closed	-$305K	–	460
2021 Q4	$305K	Sell	2,829 -2,040	-42%	-$223K	0.02%	283
2021 Q3	$533K	Hold	4,869	–	–	0.03%	243
2021 Q2	$456K	Buy	4,869 +299	+7%	+$27.5K	0.03%	273
2021 Q1	$421K	Buy	4,570 +678	+17%	+$57.2K	0.03%	278
2020 Q4	$285K	Sell	3,892 -197	-5%	-$14.6K	0.02%	295
2020 Q3	$318K	Sell	4,089 -1,220	-23%	-$83.9K	0.03%	271
2020 Q2	$295K	Sell	5,309 -16,349	-75%	-$699K	0.03%	286
2020 Q1	$642K	Sell	21,658 -23,105	-52%	-$782K	0.04%	168
2019 Q4	$1.62M	Buy	44,763 +8,170	+22%	+$250K	0.07%	133
2019 Q3	$996K	Sell	36,593 -8,070	-18%	-$209K	0.05%	187
2019 Q2	$1.07M	Buy	+44,663	New	+$1.13M	0.02%	248
2019 Q1	–	Sell	-49,572	Closed	-$969K	–	400
2018 Q4	$969K	Buy	+49,572	New	+$972K	0.02%	236

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Research's HZNP Position: Q1 2022 in Review

Advisory Research sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 2,829 shares — an estimated $305K sold.

Advisory Research first reported a position in HZNP in Q4 2018 and held it in 12 quarters. The position peaked at $1.62M in Q4 2019. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

Advisory Research reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Advisory Research sold 2,829 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $305K.
Advisory Research first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 12 quarters.
Advisory Research's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.62M in Q4 2019.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Advisory Research's 13F filing for Q1 2022, filed 16 May 2022.